Scinai Immunotherapeutics (SCNI) investor relations material

Company overview and business model

• Focuses on developing innovative immunology therapies and operates a contract development and manufacturing organization (CDMO).

• Pipeline includes therapeutic candidates licensed from the Max Planck Society and a CDMO business acquired via Recipharm Israel Ltd.

• CDMO provides integrated development and manufacturing services, including small-molecule and biologics capabilities.

• Recent strategic shift to prioritize NanoAb platform and CDMO growth after terminating an option to acquire Pincell S.r.l.

Financial performance and metrics

• As of June 30, 2026, cash and cash equivalents were $2.65 million (actual), $3.75 million (pro forma), and $9.11 million (pro forma as adjusted for the offering).

• Accumulated deficit stands at $124.3 million, with total shareholders' equity at $11.7 million (actual) and $18.2 million (pro forma as adjusted).

• Approximately $1.1 million has been raised from the sale of 473,275 ADSs to YA under the Purchase Agreement as of the filing date.

Use of proceeds and capital allocation

• Proceeds from the sale of ADSs to YA (up to $15 million, with $1.1 million received to date) will be used for pipeline development, CDMO business support, and general corporate purposes.

• Management has broad discretion over the use of proceeds, which may include working capital, R&D, regulatory matters, and capital investment.

• Pending use, proceeds may be invested in capital preservation instruments.